Analysts Set Savara Inc (NASDAQ:SVRA) Target Price at $8.83

Shares of Savara Inc (NASDAQ:SVRA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six ratings firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $8.83.

A number of equities research analysts recently weighed in on the stock. JMP Securities restated a "market outperform" rating and issued a $9.00 target price on shares of Savara in a report on Thursday, December 19th. Wells Fargo & Company assumed coverage on shares of Savara in a report on Friday, December 20th. They set an "overweight" rating and a $8.00 price objective on the stock.

Savara Stock Down 1.0 %

Shares of NASDAQ SVRA traded down $0.03 during midday trading on Monday, hitting $2.86. 4,048,566 shares of the stock traded hands, compared to its average volume of 1,261,441. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. Savara has a one year low of $2.26 and a one year high of $5.34. The business has a 50 day moving average price of $2.73 and a two-hundred day moving average price of $3.33. The company has a market cap of $490.83 million, a PE ratio of -6.65 and a beta of 0.60.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in SVRA. Vestal Point Capital LP boosted its position in Savara by 33.2% during the fourth quarter. Vestal Point Capital LP now owns 10,775,000 shares of the company's stock worth $33,079,000 after purchasing an additional 2,685,000 shares during the period. Frazier Life Sciences Management L.P. grew its stake in Savara by 6.2% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 8,660,379 shares of the company's stock valued at $26,587,000 after buying an additional 502,994 shares in the last quarter. Wellington Management Group LLP raised its holdings in Savara by 22.9% during the 3rd quarter. Wellington Management Group LLP now owns 8,624,012 shares of the company's stock valued at $36,566,000 after acquiring an additional 1,608,522 shares during the period. Vanguard Group Inc. raised its stake in shares of Savara by 4.6% during the 4th quarter. Vanguard Group Inc. now owns 8,309,970 shares of the company's stock valued at $25,512,000 after purchasing an additional 365,959 shares during the period. Finally, Deerfield Management Company L.P. Series C boosted its stake in Savara by 23.2% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 7,964,000 shares of the company's stock worth $24,449,000 after purchasing an additional 1,498,223 shares during the period. Hedge funds and other institutional investors own 87.93% of the company's stock.

Remove Ads

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.